Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Potential Benefits, Pitfalls of Biosimilars Reviewed at EULAR 2016

  |  Issue: September 2016  |  

“I have learned a lot more from biosimilar companies by now than originators ever taught me,” he said. “So I think that’s a great advantage to the medical community.”

Thomas R. Collins is a freelance medical writer based in Florida.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014 Jan;73(1):198–206.
  2. Dorner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016 Jun;75(6):974–982.

Related Articles

    Quadruple-threat Rheumatologist

    In Norway and on the international front, Tore Kvien, MD, PhD, has propelled clinical research to new levels

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Antibodies to Remicade Cross-React with Biosimilar Remsima

    NEW YORK (Reuters Health)—Antibodies to infliximab in patients with inflammatory bowel disease (IBD) treated with Janssen’s Remicade cross-react with the biosimilar Remsima from Celltrion (distributed as Inflectra by Hospira in the U.S.), researchers from Israel report. “The cross-reactivity of anti-Remicade antibodies with Remsima attests to shared immune triggering points (epitopes) on these two agents, and…